Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Johan Gagnière

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1820-3362; OpenAlex author ID A5020017074. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 7

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  3. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancr… Last author DOI 10.1177/17588359241259635↗
  4. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  5. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  6. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Co-author DOI 10.1097/ftd.0000000000000399↗
  7. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? Co-author DOI 10.1186/1477-7819-12-347↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Denis Pezet · 2 shared papers, 2014–2024 · strength 0.26
  2. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  3. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  4. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  5. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  6. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  7. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  8. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.22
  9. Stijn R. van Roessel · 2 shared papers, 2020–2025 · strength 0.22
  10. Frederik Christiaan Berrevoet · 2 shared papers, 2020–2025 · strength 0.22
  11. Kevin C. Conlon · 2 shared papers, 2020–2025 · strength 0.22
  12. Eran van Veldhuisen · 2 shared papers, 2020–2025 · strength 0.22
  13. Thilo Hackert · 2 shared papers, 2020–2025 · strength 0.22
  14. Isabella M. Frigerio · 2 shared papers, 2020–2025 · strength 0.22
  15. Giovanni Butturini · 2 shared papers, 2020–2025 · strength 0.22
  16. Quisette P. Janssen · 2 shared papers, 2020–2025 · strength 0.22
  17. Hanneke W.M. van Laarhoven · 2 shared papers, 2020–2025 · strength 0.22
  18. Keith John Roberts · 2 shared papers, 2020–2025 · strength 0.22
  19. Bas Groot Koerkamp · 2 shared papers, 2020–2025 · strength 0.22
  20. Oonagh M. Griffin · 2 shared papers, 2020–2025 · strength 0.22
  21. Rupaly Pandé · 2 shared papers, 2020–2025 · strength 0.22
  22. Mickaël Lesurtel · 2 shared papers, 2020–2025 · strength 0.22
  23. António Sá Cunha · 2 shared papers, 2020–2025 · strength 0.22
  24. Gianpaolo Balzano · 2 shared papers, 2020–2025 · strength 0.22
  25. Marc G. Besselink · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.